Evidence map›Paper›PMID 24901982›Full record

ArticlePloS one2014

Strong decrease in streptomycin-resistance and absence of XDR 12 years after the Reorganization of the National Tuberculosis Control Program in the Central Region of Cameroon.

Larissa Kamgue Sidze, Emmanuel Mouafo Tekwu, Christopher Kuaban, Jean-Paul Assam Assam, Jean-Claude Tedom, Sara Eyangoh, François-Xavier Fouda, Désiré Nolna, Francine Ntoumi, Matthias Frank and 1 more

Abstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Larissa Kamgue SidzeLaboratory for Tuberculosis Research (LTR), Biotechnology Center (BTC), University of Yaoundé I, Yaoundé, Cameroon; Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany; Central African Network for Tuberculosis, AIDS/HIV and Malaria (CANTAM), Brazzaville, Congo.
Emmanuel Mouafo TekwuLaboratory for Tuberculosis Research (LTR), Biotechnology Center (BTC), University of Yaoundé I, Yaoundé, Cameroon; Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany; Central African Network for Tuberculosis, AIDS/HIV and Malaria (CANTAM), Brazzaville, Congo.
Christopher KuabanPneumology Unit, Jamot Hospital, Yaoundé, Cameroon.
Jean-Paul Assam AssamLaboratory for Tuberculosis Research (LTR), Biotechnology Center (BTC), University of Yaoundé I, Yaoundé, Cameroon; Central African Network for Tuberculosis, AIDS/HIV and Malaria (CANTAM), Brazzaville, Congo.
Jean-Claude TedomLaboratory for Tuberculosis Research (LTR), Biotechnology Center (BTC), University of Yaoundé I, Yaoundé, Cameroon; Central African Network for Tuberculosis, AIDS/HIV and Malaria (CANTAM), Brazzaville, Congo.
Sara EyangohMycobacteriology Service, Reference laboratory of NTP, Centre Pasteur of Cameroon-Pasteur Institute International Network, Yaoundé, Cameroon.
François-Xavier FoudaMbalmayo District Hospital, Mbalmayo, Cameroon.
Désiré NolnaNational Tuberculosis Control Program (NTCP), Yaoundé, Cameroon.
Francine NtoumiFondation Congolaise pour la Recherche Médicale, Université Marien Ngouabi, Brazzaville, Congo; Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany; Central African Network for Tuberculosis, AIDS/HIV and Malaria (CANTAM), Brazzaville, Congo.
Matthias FrankInstitute of Tropical Medicine, University of Tübingen, Tübingen, Germany; Deutsches Zentrum für Infektionsforschung (DZIF), Tübingen, Germany; Central African Network for Tuberculosis, AIDS/HIV and Malaria (CANTAM), Brazzaville, Congo.
Véronique N Penlap BengLaboratory for Tuberculosis Research (LTR), Biotechnology Center (BTC), University of Yaoundé I, Yaoundé, Cameroon; Central African Network for Tuberculosis, AIDS/HIV and Malaria (CANTAM), Brazzaville, Congo.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the 1990s, resistance rates of 15% for streptomycin-resistance and 0.6% for multidrug-resistance (MDR) were reported from the Central Region of Cameroon. This work assesses drug resistant tuberculosis in this region 12 years after reorganization of the National Tuberculosis Control Program (NTCP).

methodsThis cross-sectional study was conducted from April 2010 to March 2011 in Jamot Hospital in Yaoundé, Cameroon. Only patients with smear positive pulmonary tuberculosis were included. Sputa were cultured and subsequently underwent drug susceptibility testing (DST). All consenting individuals were tested for their HIV status.

resultsA total of 665 smear positive pulmonary tuberculosis patients were enrolled. The HIV prevalence was 28.5% (95%CI [25.2-32.1]). Of the 582 sputa that grew Mycobacterium tuberculosis complex species, DST results were obtained for 576. The overall resistance rate was 10.9% (63/576). The overall resistance rates for single drug resistance were: isoniazid-resistance 4.7% (27/576), streptomycin-resistance 3.3% (19/576), rifampicin-resistance 0.2% (1/576), kanamycin-resistance 0.2% (1/576) and ofloxacin-resistance 0.2% (1/576). The MDR rate was 1.1% (6/576) and no extensively drug resistant tuberculosis (XDR) was detected.

conclusionsThe data show that reorganization of the NTCP resulted in a strong decrease in streptomycin-resistance and suggest that it prevented the emergence of XDR in the Central Region of Cameroon.

Indexed as

Drug Resistance, Multiple, BacterialAdolescentAdultAgedAged, 80 and overAntitubercular AgentsCameroonCross-Sectional StudiesExtensively Drug-Resistant TuberculosisFemaleHumansMaleMicrobial Sensitivity TestsMiddle AgedMycobacterium tuberculosisNational Health ProgramsAntitubercular AgentsStreptomycin

Identifiers

PMID24901982
PMCPMC4047025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.